Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Neurogen Corporation (NasdaqNM:NRGN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 14Earnings Announcement
Aug 13Earnings Announcement
Location
35 Northeast Industrial Road
Branford, CT 06405
Phone: (203) 488-8201
Fax: (203) 481-8683
Email: aenders@nrgn.com
Employees (last reported count): 187
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 68%
·Over the last 6 months:
 · 11 insider buys; 419.0K shares (3.7% of insider shares)
 · 2 insider sells; 11.0K shares
·Institutional: 36% (112% of float)
(101 institutions)
·Net Inst. Buying: 862.0K shares (+12.09%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Neurogen Corporation is a drug discovery company that applies its proprietary discovery platform to discover and commercialize new drugs for a broad range of pharmaceutical uses. The Company is focused on discovering new small molecule drugs (i.e. drugs that can be taken as a pill) for large market disorders where existing therapies achieve limited therapeutic effects or produce unsatisfactory side effects. In multiple programs, the Company has applied its AIDD (Accelerated Intelligent Drug Discovery) platform to discover drug candidates that work through well validated biological targets in the body, but for which the pharmaceutical industry has had limited or no success in discovering viable drug candidates.
More from Market Guide: Expanded Business Description

Financial Summary
Neurogen Corp. is a pharmaceutical company engaged in the discovery and development of a new generation of drugs which are designed to selectively regulate the communication between cells in order to influence cell function. For the six months ended 6/30/01, revenues fell 28% to $5.2 million. Net loss before acct. change rose 1% to $13.6 million. Results reflect reduced amounts earned from Pfizer, partially offset by lower stock compensation costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Frank Carlucci, 70
Chairman
--  --  
Harry Penner, Jr., 55
Vice Chairman, Pres, CEO
$1.9M$3.3M
Stephen Davis, 40
Sr. VP and CBO
1.1M673K
Alan Hutchison, Ph.D., 47
Sr. VP-Drug Discovery
1.2M385K
Kenneth Shaw, Ph.D., 44
Sr. VP - Chemistry and Pre-Clinical Devel.
999K350K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:NRGNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$16.125
Recent Price$18.98 
52-Week High
on 13-Sep-2000
$41.00 
Beta0.70 
Daily Volume (3-month avg)68.6K
Daily Volume (10-day avg)9,000 
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-51.0%
52-Week Change
relative to S&P500
-34.3%
Share-Related Items
Market Capitalization$331.0M
Shares Outstanding17.4M
Float5.60M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$6.56 
Earnings (ttm)-$0.87 
Earnings (mrq)-$0.33 
Sales (ttm)$1.03 
Cash (mrq)$5.33 
Valuation Ratios
Price/Book (mrq)2.89 
Price/EarningsN/A 
Price/Sales (ttm)18.45 
Income Statements
Sales (ttm)$18.4M
EBITDA (ttm)-$19.9M
Income available to common (ttm)-$15.1M
Profitability
Profit Margin (ttm)-82.2%
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-10.88%
Return on Equity (ttm)-12.39%
Financial Strength
Current Ratio (mrq)7.87 
Debt/Equity (mrq)0.02 
Total Cash (mrq)$93.0M
Short Interest
As of 8-Aug-2001
Shares Short44.0K
Percent of Float0.8%
Shares Short
(Prior Month)
34.0K
Short Ratio0.72 
Daily Volume61.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.